홈 페이지모든 분자Axl
Axl
Axl
Axl 분자 정보
Molecule Name
AXL receptor tyrosine kinase
분자 별명
AXL,UFO
Drug Development Progress
임상 약물 수27
시판 약물 수2
최고 연구 개발 단계Approved
표적 별명
EC:2.7.10.1，EC 2.7.10，UFO，AXL Transforming Sequence/Gene，AXL Oncogene，EC 2.7.10.1，JTK11，Tyro7，ARK，Tyrosine-protein kinase receptor UFO，AXL，AXL Receptor Tyrosine Kinase
분자 배경
AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.
Axl 제품 목록
No Data
You Have Viewed 0 Of 0 Results
- 1
No Data
No Data
Can’t find what you need?
Submit your requirements and our technical
team will help.
라이선싱 협력
| 프로젝트 이름 | 약물 유형 | 치료 영역 | 적응증 | 단계 | 권리 지역 |
|---|---|---|---|---|---|
| AXL inhibitor | Small molecule | Oncology/Cancer | STK11_mut NSCLC,other cancers | Phase I | Global |
- 프로젝트 이름
- AXL inhibitor
- 약물 유형
- Small molecule
- 치료 영역
- Oncology/Cancer
- 적응증
- STK11_mut NSCLC,other cancers
- 단계
- Phase I
- 권리 지역
- Global
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Batiraxcept | S6-500c; 3D-229; 3D229; 3D-299; Ruga-S6; AB-007; AVB 500; AVB-500; Aravive S-6; AVB-S6-500 | Phase 3 Clinical | Aravive Inc | Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Fallopian Tube Neoplasms; Glomerulonephritis, IGA; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Uterine Neoplasms | 상세 |
| KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Hematologic Neoplasms; Neoplasm Metastasis; Sarcoma, Ewing; Solid tumours; Thymus Neoplasms | 상세 |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516 | Phase 3 Clinical | Mirati Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | 상세 |
| Butylidenephthalide | NSC-325307; LF-001 (Everfront Biotech); EF-001; HK-001; BDPH | Phase 3 Clinical | Everfront Biotech Co Ltd | Amyotrophic Lateral Sclerosis; Glioblastoma; Glioma | 상세 |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| Mecbotamab vedotin | BA-3011; BA3011; BA 3011 | Phase 2 Clinical | Bioatla | Carcinoma, Non-Small-Cell Lung; Dermatofibrosarcoma; Ovarian Neoplasms; Sarcoma | 상세 |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | 상세 |
| Tamnorzatinib | ONO-7475 | Phase 2 Clinical | Ono Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancreatic Neoplasms; Solid tumours | 상세 |
| Bemcentinib | BGB-324; R-428; BGB-3234 | Phase 2 Clinical | Rigel Pharmaceuticals Inc | Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; CNS Embryonal Tumor; Coronavirus Disease 2019 (COVID-19); Glioblastoma; Inflammatory Breast Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Melanoma; Mesothelioma; Myelodysplastic Syndromes; Pancreatic Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| Enapotamab vedotin | AXL-107-MMAE | Phase 2 Clinical | Genmab A/S, Seagen Inc | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Melanoma; Ovarian Neoplasms; Sarcoma; Solid tumours; Thyroid Neoplasms; Uterine Cervical Neoplasms | 상세 |
| CD73/AXL.HypoSti.CAR-T cells therapy (Pla General Hospital) | Phase 2 Clinical | Pla General Hospital | Solid tumours | 상세 | |
| FC-084-CSA | FC084CSA; FC-084-CSA | Phase 2 Clinical | FindCure Biosciences (ZhongShan) Co Ltd | Solid tumours | 상세 |
| Adrixetinib | Q-702 | Phase 2 Clinical | Lead Discovery Center GmbH, Max Planck Institute of Biochemistry, Vichem Chemie | Blastic Plasmacytoid Dendritic Cell Neoplasm; Carcinoma, Hepatocellular; Central Nervous System Lymphoma; Erdheim-Chester Disease; Esophageal Neoplasms; Graft vs Host Disease; Hematologic Neoplasms; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Histiocytosis, Sinus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Lymphoma, Follicular; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Neoplasms, Plasma Cell; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia | 상세 |
| Dubermatinib | TP-0903 | Phase 1 Clinical | Sumitomo Dainippon | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Melanoma; Ovarian Neoplasms; Solid tumours | 상세 |
| INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Squamous Cell Carcinoma of Head and Neck | 상세 |
| BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | 상세 |
| A-416 | A416; A-416 | Phase 1 Clinical | Klus Pharma Inc | Solid tumours | 상세 |
| NTQ-2494 | NTQ2494; NTQ-2494 | Phase 1 Clinical | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Solid tumours | 상세 |
| CTS-2016 | CTS-2016 | Phase 1 Clinical | CytosinLab Therapeutics Co Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 상세 |
| Ligritinib | AB-801 | Phase 1 Clinical | Arcus Biosciences Inc | Neoplasms | 상세 |
| XZB-0004 | XZB-0004; SLC-0211; SLC-391 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Myelodysplastic Syndromes; Solid tumours | 상세 |
| NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | 상세 |
| TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | 상세 |
| AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | 상세 |
| Denfivontinib Hydrochloride | SKI-G-801; G-801; G-749 Hydrochloride | Phase 1 Clinical | Genosco | Leukemia, Myeloid, Acute; Solid tumours | 상세 |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Nanjing Nadingfei Pharmaceutical Technology Co Ltd, Shijiazhuang No 4 Pharmaceutical Co Ltd | Liver Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lung Neoplasms; Renal Insufficiency; Solid tumours | 상세 |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | 상세 |